Literature DB >> 9023653

Bactericidal activity, post antibiotic effect and modified controlled effective regrowth time of meropenem at high concentrations.

K E Bowker1, H A Holt, D S Reeves, A P MacGowan.   

Abstract

The effect of increasing meropenem concentrations up to 250 mg/L, as might occur if 3 g was given as a single daily intravenous dose, was investigated in terms of bactericidal activity, post antibiotic effect (PAE) and modified controlled effective regrowth time (mCERT). Increasing the meropenem concentration above 50 mg/L did not result in increased bacterial killing, while concentrations over 75 mg/L did not result in longer PAE or mCERT.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9023653     DOI: 10.1093/jac/38.6.1055

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

Review 1.  Comparative pharmacokinetics of the carbapenems: clinical implications.

Authors:  J W Mouton; D J Touzw; A M Horrevorts; A A Vinks
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Factors influencing the clinical outcome of methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  M S Albur; K Bowker; I Weir; A MacGowan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-06-14       Impact factor: 3.267

Review 3.  Meropenem: an updated review of its use in the management of intra-abdominal infections.

Authors:  M N Lowe; H M Lamb
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

Review 4.  Continuous infusion of beta-lactam antibiotics.

Authors:  A P MacGowan; K E Bowker
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

5.  Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.

Authors:  Alasdair P MacGowan; Karen E Bowker; Alan R Noel
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.